^
Association details:
Biomarker:No biomarker
Cancer:Prostate Cancer
Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Prostate Cancer: Systemic Therapy for M1 CRPC…First-line and subsequent treatment options...Atezolizumab/carboplatin/etoposide (category 3)
Secondary therapy:
carboplatin + etoposide oral